Evolent Health (EVH) Tops Q1 EPS by 5c, Offers Guidance

Evolent Health (NYSE: EVH) reported Q1 EPS of ($0.01), $0.05 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $215.1 million versus the consensus estimate of $212.79 million.

GUIDANCE:

Evolent Health sees Q2 2021 revenue of $210-225 million, versus the consensus of $212 million.

Evolent Health sees FY2021 revenue of $845-880 million, versus the consensus of $865 million.

For earnings history and earnings-related data on Evolent Health (EVH) click here.

You May Also Be Interested In

• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Pfizer reaffirms 2026 guidance after CFO transition news
• JPMorgan Upgrades Sika AG (SIKA:SW) (SKFOF) to Neutral